TRADING UPDATES: Molten Ventures completes raise; Saietta proposes one
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
Read moreTo deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.
Find out MoreWed, 06th Jan 2021 08:36
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
Read moreSyncona Ltd - London-based investor in healthcare companies - Agrees to acquire all remaining stock in investee Freeline Therapeutics Holdings PLC for USD6.50 in cash per share, valuing Freeline at approximately USD28.3 million. Syncona currently owns 49.7% of shares in Freeline. The company will provide up to USD15 million of financing in conjunction with the acquisition to enable Freeline to meet its near-term cash requirements and continue advancing its lead programme FLT201, a potential gene therapy for Gaucher disease.
Read more(Alliance News) - Syncona Ltd on Thursday said net asset value decreased as it swung to a negative return in its latest half year, but that it is well-positioned for future growth thanks to its "rich pipeline".
Read more(Sharecast News) - Life science specialist Syncona reported a net asset value of £1.2bn at the end of its first half on Thursday, down from £1.25bn on 31 March, with a net asset value return of -4.2% during the period.
Read moreSyncona Ltd - London-based investor in healthcare companies - Says portfolio company Achilles Therapeutics reports that pretax loss widened to USD16.7 million in the third quarter of 2023 from USD12.4 million the year before, as operating expenses rose 19% to USD19.1 million from USD16.0 million a year ago. Achilles is a Philadelphia, US-based clinical-stage biopharmaceutical company which develops novel cancer immunotherapies. Syncona owns a 25% stake in Achilles.
Read moreFriday 10 November | |
Allianz Technology Trust PLC | Q3 Results |
Wheaton Precious Metals Corp | Q3 Results |
Monday 13 November | |
Bank of Cyprus Holdings PLC | Q3 Results |
British Land Co PLC | Half Year Results |
Kainos Group PLC | Half Year Results |
Team Internet Group PLC | Q3 Results |
Tuesday 14 November | |
ActiveOps PLC | Half Year Results |
Babcock International Group PLC | Half Year Results |
Bank of Georgia Group PLC | Q3 Results |
Castings PLC | Half Year Results |
ConvaTec Group PLC | Trading Statement |
DCC PLC | Half Year Results |
Forterra PLC | Half Year Results |
Gear4Music PLC | Half Year Results |
Genel Energy PLC | Trading Statement |
HydrogenOne Capital Growth PLC | Q3 Results |
Hill & Smith PLC | Trading Statement |
Imperial Brands PLC | Full Year Results |
Informa PLC | Trading Statement |
Land Securities Group PLC | Half Year Results |
Oxford Instruments PLC | Half Year Results |
Picton Property Income Ltd | Half Year Results |
Renalytix PLC | Q1 Results |
Vesuvius PLC | Trading Statement |
Vodafone Group PLC | Half Year Results |
Wise PLC | Half Year Results |
Wednesday 15 November | |
Diversified Energy Co PLC | Trading Statement |
Experian PLC | Half Year Results |
Fuller, Smith & Turner PLC | Half Year Results |
Genuit Group PLC | Trading Statement |
Intermediate Capital Group PLC | Half Year Results |
Ninety One PLC and Ltd | Half Year Results |
Renold PLC | Half Year Results |
SSE PLC | Half Year Results |
Synthomer PLC | Trading Statement |
Tracsis PLC | Full Year Results |
Tullow Oil PLC | Trading Statement |
Warehouse REIT PLC | Half Year Results |
Thursday 16 November | |
Assura PLC | Half Year Results |
Atalaya Mining PLC | Q3 Results |
Aviva PLC | Trading Statement |
Burberry Group PLC | Half Year Results |
Close Brothers Group PLC | Trading Statement |
CMC Markets PLC | Half Year Results |
Crest Nicholson Holdings PLC | Trading Statement |
Halma PLC | Half Year Results |
Great Portland Estates PLC | Half Year Results |
Kier Group PLC | Trading Statement |
International Distributions Services PLC | Half Year Results |
Investec PLC and Ltd | Half Year Results |
Liontrust Asset Management PLC | Half Year Results |
Manolete Partners PLC | Half Year Results |
Melrose Industries PLC | Trading Statement |
Norcros PLC | Half Year Results |
Premier Foods PLC | Half Year Results |
Qinetiq Group PLC | Half Year Results |
Spirax-Sarco Engineering PLC | Trading Statement |
Syncona Ltd | Half Year Results |
Tatton Asset Management PLC | Half Year Results |
Tyman PLC | Trading Statement |
United Utlities Group PLC | Half Year Results |
Young & Co's Brewery PLC | Half Year Results |
Copyright 2023 Alliance News Ltd. All Rights Reserved. |
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday, Thursday and Friday and not separately reported by Alliance News:
Read moreSyncona Ltd - London-based investor in healthcare companies - Says Syncona Investment Management Ltd has submitted a non-binding proposal to acquire the entire remaining share capital of Freeline Therapeutic Holdings PLC. Offers upfront cash consideration of USD5.00 per American depository share, representing a 20% premium over the USD4.16 volume weighted average price from October 4 to October 16. Syncona currently owns around 57.9% of shares in Stevenage, England-based Freeline, which it co-founded in 2015. Freeline aims to develop gene therapies to treat chronic diseases, most notably its potentially "transformative" FLT201 programme to treat Gaucher disease.
Read more(Alliance News) - Syncona Ltd on Wednesday said its portfolio company Freeline Therapeutics Holdings PLC has received positive initial safety, tolerability and enzyme activity data from its FLT201 trial for the treatment of Gaucher disease.
Read moreSyncona Ltd - London-based investor in healthcare companies - Launches share buyback programme worth up to GBP40.0 million, to be conducted by Numis Securities Ltd. Says core focus remains on allocating capital to portfolio companies' assets. However the buyback is necessary due to Syncona's shares currently trading at a discount to net asset value, which was 184.6 pence per share at June 30. Says buyback will not affect investments into clinical stage assets planned for the next 24 months. Company expects that capital deployment into portfolio and pipeline will total between GBP150 million and GBP200 million for the year ending March 31, in line with prior guidance. Chair Melanie Gee says Syncona "has a high level of confidence in our portfolio and its valuation".
Read more(Sharecast News) - Syncona shares fell as the UK healthcare investment firm said Novartis had stopped the development of experimental eye treatment, GT005, resulting in milestone payments write-off of £54.5m for Gyroscope Holdings in which Syncona once held a 54% stake.
Read more(Alliance News) - Syncona Ltd on Monday said it has been informed by Swiss-American pharmaceutical company Novartis AG that the development of eye treatment, GT005, for geographic atrophy secondary to dry age-related macular degeneration will be discontinued.
Read more(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.
Read moreSyncona Ltd - London-based healthcare investor - Notes second quarter results announcement from its Nasdaq-listed portfolio company Freeline Therapeutics Holdings PLC. Says the key highlights include Freeline completing the dosing in the first dose cohort of the phase 1/2 trial of FLT201 in Gaucher disease, following dosing of the second patient. Says initial clinical data from the FLT201 trial is expected in the second half of 2023. Also says Freeline has a cash position of USD38.8 million at June 30 compared to USD55.4 million on March 31, which Freeline expects will enable the company to fund its planned operations into the second quarter of 2024. Freeline says net income in the three months that ended June 30 narrowed to USD14.8 million from USD51.1 million a year earlier.
Read moreSyncona Ltd - London-based healthcare investor - Net asset value at June 30 is 184.6 pence per share, down 1.0% from 186.5p on March 31. NAV total return also was negative 1.0% for the recent three months, Syncona's financial first quarter. Notes performance was hurt by "negative foreign exchange movements" across its life science portfolio. This is valued at GBP628.7 million on June 30, up 4.0% from GBP604.6 million on March 31.
Read more